Eletriptan: a review and new perspectives (Q36641480)

15 August 2017

1 reference

title

Eletriptan: a review and new perspectives (English)

1 reference

15 August 2017

1 reference

3

Giuseppe Nappi

1 reference

15 August 2017

1

Giorgio Sandrini

1 reference

15 August 2017

2

Armando Perrotta

1 reference

15 August 2017

1 October 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

15 August 2017

1 reference

15 August 2017

6

1 reference

15 August 2017

10

1 reference

15 August 2017

1413-1421

1 reference

The International Classification of Headache Disorders: 2nd edition

15 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Migraine: epidemiology, impact, and risk factors for progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Incidence of primary headache: a Danish epidemiologic follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Burden of migraine in the United States: disability and economic costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Lost Productive Time and Cost Due to Common Pain Conditions in the US Workforce

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

The pharmacology of headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Tolerability and Safety of Eletriptan in the Treatment of Migraine: A Comprehensive Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Effect of high-dose intravenous eletriptan on coronary artery diameter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

The pharmacokinetics and safety of single escalating oral doses of eletriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Pharmacological treatments for acute migraine: quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Effectiveness of eletriptan in reducing time loss caused by migraine attacks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

An economic evaluation of triptan products for migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Efficacy of Eletriptan in Migraineurs With Persistent Poor Response to Nonsteroidal Anti‐inflammatory Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: results from a multiple-attack study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Oral zolmitriptan is effective in the acute treatment of cluster headache.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Naratriptan in the preventive treatment of cluster headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Eletriptan for the short-term prophylaxis of cluster headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Symptomatic treatment of migraine in children: a systematic review of medication trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1413

10.1586/14737175.6.10.1413

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17078782